151 related articles for article (PubMed ID: 36776544)
1. The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis.
Liu T; Zhuo L
J Environ Public Health; 2023; 2023():6222324. PubMed ID: 36776544
[TBL] [Abstract][Full Text] [Related]
2. C-reactive Protein Is a Predictor of Prognosis of Prostate Cancer: A Systematic Review and Meta-Analysis.
Liao DW; Hu X; Wang Y; Yang ZQ; Li X
Ann Clin Lab Sci; 2020 Mar; 50(2):161-171. PubMed ID: 32366552
[TBL] [Abstract][Full Text] [Related]
3. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
[TBL] [Abstract][Full Text] [Related]
4. Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients.
Graff JN; Beer TM; Liu B; Sonpavde G; Taioli E
Clin Genitourin Cancer; 2015 Aug; 13(4):e217-e221. PubMed ID: 25735198
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.
Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Asatryan L; Wirth MP; Siegert G
Inflamm Res; 2013 Dec; 62(12):1063-72. PubMed ID: 24061501
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of C-reactive protein in prognosis evaluation of prostate cancer: a systematic review and meta-analysis.
Du J; Lan J; Xiong J; Yang H; Xu X; Tang C; Huang G; Ying Q; Mu J; Hu Q
Transl Cancer Res; 2021 Oct; 10(10):4432-4439. PubMed ID: 35116300
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.
Pierce BL; Biggs ML; DeCambre M; Reiner AP; Li C; Fitzpatrick A; Carlson CS; Stanford JL; Austin MA
Cancer Causes Control; 2009 Sep; 20(7):1193-203. PubMed ID: 19267250
[TBL] [Abstract][Full Text] [Related]
11. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
Front Immunol; 2022; 13():827788. PubMed ID: 35211122
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of C-reactive protein in patients with head and neck squamous cell carcinoma: A meta-analysis.
Chen Y; Cong R; Ji C; Ruan W
Cancer Med; 2020 Dec; 9(24):9541-9553. PubMed ID: 33201589
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation across C-reactive protein and risk of prostate cancer.
Markt SC; Rider JR; Penney KL; Schumacher FR; Epstein MM; Fall K; Sesso HD; Stampfer MJ; Mucci LA
Prostate; 2014 Jul; 74(10):1034-42. PubMed ID: 24844401
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis.
Yu A; Guo K; Qin Q; Xing C; Zu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 33635319
[TBL] [Abstract][Full Text] [Related]
15. The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers.
O'Brian D; Prunty M; Hill A; Shoag J
Front Immunol; 2021; 12():721989. PubMed ID: 34512646
[TBL] [Abstract][Full Text] [Related]
16. Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients.
Xu L; Zhao Q; Huang S; Li S; Wang J; Li Q
Tumour Biol; 2015 Feb; 36(2):669-73. PubMed ID: 25286759
[TBL] [Abstract][Full Text] [Related]
17. A predictive role of C-reactive protein in colorectal cancer risk: an updated meta-analysis from 780,985 participants and 11,289 cancer cases.
Han L; Guo Y; Ren D; Hui H; Li N; Xie X
Int J Colorectal Dis; 2023 May; 38(1):121. PubMed ID: 37160817
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis.
Rocha P; Morgan CJ; Templeton AJ; Pond GR; Naik G; Sonpavde G
Oncol Res Treat; 2014; 37(12):772-6. PubMed ID: 25531724
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein and procalcitonin levels in prostate cancer.
Ilktac A; Kalkan S; Caliskan S
Int J Clin Pract; 2021 Apr; 75(4):e13935. PubMed ID: 33326672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
